NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio
PRESS RELEASENanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug PortfolioFORT WORTH, Texas ...
NanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio
PRESS RELEASENanOlogy Appoints David J. Arthur as Chief Executive Officer to Drive Clinical Development of its Large Surface Area Microparticle (LSAM) Investigational Drug Portfolio FORT WORTH, Texas, ...
NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor
PRESS RELEASE NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor Next Generation Intratumoral Technology Targets Diffuse Intrinsic Pontine Glioma Investigational New Drug ...